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Abstract
Objective: To determine the cognitive profile of adult patients with mitochon-
drial disease, and the effect of disease severity on cognition. Methods: Using a
prospective case-control design, we compared cognition of patients to norma-
tive data and to matched controls, assessed three times over 18 months. Forty-
nine patients with m.3243A>G (N = 36) and m.8344A>G (N = 13) mtDNA
mutations and 32 controls, matched by age (5 years) and premorbid cogni-
tion (10 WTAR FSIQ points), participated. Participants completed neuropsy-
chological assessments of general cognition (WAIS-IV), executive function (D-
KEFS), and memory (WMS-IV). Potential predictors of cognition were
explored. Results: Patients show mild-to-moderate premorbid cognitive impair-
ment, but substantial impairment in current general cognition and distinct
domains, including verbal comprehension, perceptual reasoning, working mem-
ory, processing speed, and memory retrieval. Executive dysfunction may be
caused by slower decision-making. Patients performed worse than controls,
except on memory tasks, indicating intact memory, when premorbid cognition
is controlled for. Premorbid cognition and disease severity were consistent pre-
dictors of cognition in patients; however, cognitive decline appears slow and is
unlikely in the short-term, when other disease-specific factors remain stable.
Interpretation: Patients should be monitored to facilitate early identification of
a complex profile of cognitive deficits and individuals with higher disease bur-
den should be followed up more closely. On development of cognitive difficul-
ties, appropriate compensatory strategies should be determined through in-
depth assessment. Using strategies such as slower presentation of information,
multiple modes of presentation, active discussion to aid understanding and
decision-making, and use of memory aids, may ameliorate difficulties.
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Introduction
Mitochondrial diseases are a common group of genetic
neuromuscular disorders characterized by genotypic and
phenotypic heterogeneity with a prevalence comparable to
many other genetically determined neurodegenerative dis-
eases.1 Neurological features in adult patients with mito-
chondrial disease are prominent and include ataxia,
seizures, stroke-like episodes, migraine, psychiatric features,
and encephalopathy. Whilst there is significant clinical vari-
ability, neurological impairment remains one of the hall-
marks of mitochondrial disease and cognitive impairment,
currently, is one of the least understood aspects.
In patients with mitochondrial disease, high rates of
cognitive delay, cognitive and memory impairment, and
dementia have been reported in small case studies and
review articles only. However, these studies are primarily
a retrospective analysis of patients manifesting high geno-
typic variability and disease burden.
Focal cognitive deficits of memory, executive function-
ing, visuospatial abilities, and processing speed have been
reported in small-scale, systematic investigations carried
out at a single time point, with marked variability in
results.2–11 While studies have suggested mtDNA geno-
type-specific differences in cognition6; group sizes have
been insufficient to identify specific profiles and cognitive
performance may better relate to disease burden.11
We sought to evaluate cognitive ability and delineate
potential predictors of cognition in patients with the
m.3243A>G and m.8344A>G-related mitochondrial dis-
eases1 compared to standardized normative data12–14 and
to age- and premorbid cognitive ability-matched control
participants over time.
Methods
Study design
We performed a prospective case-control study compar-
ing cognition in patients with mitochondrial disease to
the norm and to age- and premorbid cognitive ability-
matched controls, assessed three times over 18 months
(Fig. 1). Predictors of cognition were also explored. This
study was approved and performed under the ethical
guidelines issued by our institution and complied with
the declaration of Helsinki. All participants gave written
informed consent prior to study inclusion.
Participants
Forty-nine adult patients with mitochondrial disease, with
either m.3243A>G (N = 36) or m.8344A>G (N = 13)–re-
lated mitochondrial disease, and 32 controls matched for
age (5 years) and premorbid cognitive ability (10
Wechsler Test of Adult Reading15 (WTAR) FSIQ points)
participated. Matching criteria were designed to elucidate
cognitive change associated with mitochondrial disease,
unrelated to age or premorbid cognitive functioning. Fig-
ure 1 shows participant numbers for each sub-analysis.
Recruitment and consent process for patients with mito-
chondrial disease and controls is outlined in Figure 2.
Patient scores were compared to population-based
norms from the WTAR, WAIS-IV, D-KEFS, and WMS-IV
data manuals (Data S1).
Apparatus
Each participant completed a battery of tests assessing
premorbid cognitive ability, general cognitive ability, ver-
bal comprehension, perceptual reasoning, working mem-
ory, processing speed, executive function, and memory,
using the WTAR,15 WAIS-IV,13 D-KEFS,12 and WMS-
IV.14 Table 1 gives detailed information about cognitive
assessments used and the domains that they map on to.
Cognitive data were translated from raw scores into pop-
ulation-based standard scores using normative data12–15;
WTAR and WAIS-IV have a normative mean of 100
(SD = 15); D-KEFS and WMS-IV have a normative mean
of 10 (SD = 3), except WMS-IV recognition tasks, which
were translated into percentiles.
Figure 1. Participant numbers for each sub-analysis of study.
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WTAR FSIQ,15 number of years in education, New-
castle Mitochondrial Disease Adult Scale (NMDAS),16
mtDNA genotype, anticonvulsant medication, medication
for depression, Beck’s Depression Inventory (BDI),17
Beck’s Anxiety Inventory (BAI),18 % mtDNA mutation
level in urine,19 age, and gender were considered as pre-
dictors of cognition in patients with mitochondrial dis-
ease. Items regarding seizures, mood, and cognition were
excluded from the NMDAS score to prevent overlap in
variance with other predictors.
Procedure
WMS-IV immediate memory was assessed, followed by
delayed memory and recognition memory (and Free
Recall memory in the case of VPA) after a 20–30-min
interval, in which WAIS-IV and D-KEFS subtests were
administered. Participants also completed the WTAR,
BDI, and BAI. Cognition was assessed three times
over 18 months (baseline, 6 months, and 18 months).
At each assessment, patients with mitochondrial dis-
ease underwent physical examination by experienced
clinicians (GSG, AMS, RMF and DMT) using the
NMDAS.
Statistical analyses
Participants were compared to normative data using Z-
tests, executed in Minitab Version 16.20 They were
compared to matched control participants at baseline and
over time, using paired samples t-test, Wilcoxon signed
ranks test for paired samples, and repeated measures
ANOVA, performed in SPSS Version 19.21 Linear regres-
sion was executed in SPSS to determine predictors of cog-
nition in patients with mitochondrial disease at baseline
assessment. Data S1 gives a full description of statistical
analyses. To correct for multiple statistical analyses on
different cognitive subtests, P-values were adjusted using
the Holm method,22 which is more powerful than the
commonly used Bonferroni correction.
Results
Table 2 shows the baseline characteristics of patients with
mitochondrial disease and controls. Number of years in
education at baseline assessment differed between the
groups (Z(32) = 2.04, P = 0.042).
Patients compared to normative population
data at baseline assessment
Table S1 shows summary data for comparison of patients
to normative data on cognitive assessments.
Premorbid cognition
Patients performed significantly lower than the normative
population on the WTAR, with a pattern suggesting mild
Figure 2. Recruitment and consent process for patients mitochondrial disease and control participants.
828 ª 2019 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association.
Cognitive Deficits in Mitochondrial Disease H. L. Moore et al.
(1SD) to moderate (1.5SD) rather than severe (2SD) pre-
morbid cognitive impairment (1SD = 27%; 1.5SD = 18%;
2SD = 0%).
General cognitive functioning
Patients scored significantly lower than the normative
population on the WAIS-IV FSIQ, with high rates of
impairment at both 1SD (45%) and 2SD (22%), showing
clear evidence for current cognitive impairment. This was
reflected in significantly worse scores on all WAIS-IV sub-
tests. PRI performance was significantly better than PSI
(F(2.59) = 4.86, P = 0.005; Greenhouse-Geisser correc-
tion; PRI-PSI: P = 0.008).
Executive function
Patients performed significantly lower than the normative
population on VF subtests, with higher than expected
rates of impairment at 1SD (Letter = 31%; Category = 49%,
Switching Correct = 43%, Switching Accuracy = 27%) and
2SD cut-offs (Letter = 10%; Category = 7%, Switching
Correct = 20%, Switching Accuracy = 6%). VF Category
and VF Switching Correct did not differ significantly
(t(48) = 1.92, P = 0.061, d = 0.55), indicating normal
VF Switching performance, when taking account of seman-
tic fluency.
On the D-KEFS Tower test, patients scored signifi-
cantly worse than the norm on all subtests but the
Tower Move Accuracy Ratio. There were low to normal
rates of impairment at 1SD (Total: 16%; Time Per
Move Ratio: 33%; Move Accuracy Ratio: 6%; Rule Vio-
lations Per Item Ratio: 12%) and 2SD (Total = 6%;
Time Per Move Ratio = 25%; Move Accuracy
Ratio = 2%; Rule Violations Per Item Ratio = 4%) for
all but Time Per Move Ratio; therefore, a small num-
ber of more severely affected participants may have
skewed the results.
Table 1. Cognitive assessments used, domain of cognitive functioning that they map on to, and definition of that domain.
Test Subtest Acronym Domain of functioning Definition/Real World Context
Wechsler adult intelligence
scale-IV (WAIS-IV)13
-Full Scale IQ FSIQ General cognitive functioning Average intellectual ability across a
range of domains and skills.
-Verbal Comprehension
Index
VCI Verbal comprehension Ability to use words and language
to solve problems.e.g.
understanding more complex
language (e.g. in a consultation).
-Perceptual Reasoning
Index
PRI Visuospatial and perceptual
reasoning
Use of visual information to
understand and interact with the
environment.e.g. finding your way
around a car park, putting together
flat pack furniture.
-Processing Speed Index PSI Processing speed How quickly a person can take
information in and use it.
Delis-Kaplan executive
function system
(D-KEFS)12
-Verbal Fluency VF Verbal executive function
tapping working memory,
self-monitoring, inhibition,
task switching, and cognitive
flexibility
The control processes that guide
behavior, help you to plan what
to do, monitor whether a plan is
working, change plans if the first
isn’t working, stop yourself from
doing something that you shouldn’t.-Tower Nonverbal executive function
utilizing planning, rule learning,
and inhibition
Wechsler adult memory
scale-IV (WMS-IV)14
-Logical Memory LM Immediate, delayed, and
recognition memory for narrative
content
Ability to learn, remember, and
recall verbal information.e.g.
remembering a shopping list, a
conversation with a friend,
family member, or healthcare
professional.
-Verbal Paired
Associates
VPA Immediate, delayed, and recognition
memory for word pairs when
providing a cue, and free recall
(without a cue)
Birt Memory and
Information Processing
Speed Battery (BMIPB)35
Motor speed How quickly a person can physically
complete a simple task that does
not require any thinking. This will
impact performance on any
timed task.
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Memory
Patients scored significantly lower than the normative
population on LM I and LM II, with higher than
expected rates of impairment at 1SD (LM I = 42.86%;
LM II = 30.61%) and 2SD (LM I = 14.29%; LM
II = 12.24%). Patients demonstrated poorer free recall
than expected in relation to recognition memory
(P < 0.001). Conversely, they performed similarly to
the norm on VPA I and VPA II and patients showed sim-
ilar performance on prompted recall versus recognition
(P = 0.096). VPA Free Recall performance was
significantly worse than the norm, with higher rates
of impairment at 1SD (M = 30.61%) and 2SD
(M = 10.20%), replicating the LM free recall impairment.
Patients compared to matched controls at
baseline assessment
General cognitive functioning
Patients achieved significantly worse WAIS-IV FSIQ and
Index scores than controls (FSIQ: t(31) = 6.47,
P = 0.005, d = 2.32; VCI: t(31) = 5.96, P = 0.005,
d = 2.14; PRI: Z = 3.25, P = 0.005, r = 0.41; WMI:
t(31) = 3.52, P = 0.005, d = 1.26; PSI: Z = 4.14,
P = 0.005, r = 0.52; Table S2B). Including BMIPB Motor
Speed in a mixed model ANCOVA identified a significant
interaction between motor speed and disease status (t
(29) = 2.18, P = 0.038, d = 0.78); patients with faster
motor speed did not perform worse than matched controls,
whereas patients with slower motor speed did show PSI
decrements (Figure S1).
Executive function
Patients performed significantly worse than controls on VF
Letter (Z = 3.33, P = 0.004, r = 0.42), VF Category (t
(31) = 4.76, P = 0.004, d = 1.71), VF Switching Cor-
rect (t(31) = 3.89, P = 0.004, d = 1.40), and VF Switch-
ing Accuracy (t(31) = 4.09, P = 0.004, d = -1.47;
Table S2B). The mean difference on each VF subtest was
around 3 IQ points (Table S2B), equating to a 1SD difference.
On the D-KEFS Tower test, patients scored significantly
worse than controls on the Tower Total (Z = 3.10,
P = 0.006, r = 0.39), Time Per Move Ratio (Z = 3.18,
P = 0.004, r = 0.40), and Rule Violations Per Item
Ratio (Z = 2.52, P = 0.024, r = 0.32; Table S2B).
There was no significant difference in Move Accuracy
Ratio (Z = 0.37, P = 0.712, r = 0.05).
Memory
There was no significant difference between patients and
matched controls on any WMS-IV memory subtests
(Table S2C).
Change in patient cognition from premorbid
to current levels
Patients declined by 8.37 IQ points on average between
the WTAR and WAIS-IV, a significant change from pre-
morbid to current cognition (Z(49) = 4.44, P < 0.001,
r = 0.56). Of these, 37 patients declined between the
two measures, 11 increased, and one remained constant;
14 (29%) declined by ≥1SD.
Table 2. Baseline characteristics of participants at each time point.
Patient characteristics
Baseline patient-control
comparison
18 month patient-control
comparison
Baseline Patients Completing Study Patient Control Patient Control
N 49 42 32 32 20 20
Age (years) 46.24 (12.15) 46.76 (11.21) 47.19 (13.59) 47.25 (14.42) 43.85 (12.29) 43.35 (12.53)
Gender
Male 23 (46.94%) 19 (45.24%) 14 (43.75%) 14 (43.75%) 10 (50%) 11 (55%)
Female 26 (53.06%) 23 (54.76%) 18 (56.25%) 18 (56.25%) 10 (50%) 9 (45%)
mtDNA genotype
m.3243A>G 36 (73.47%) 33 (78.57%) 24 (75%) \ 17 (85%) \
m.8344A>G 13 (26.53%) 9 (21.43%) 8 (25%) \ 3 (15%) \
% mtDNA mutation
level in urine
60.87% (26.47) 57.52% (26.44) 58.36% (27.08) \ 56.76% (29.33) \
No. of years in
education
13.67 (2.58) 13.62 (2.64) 14.41 (2.83) 15.72 (2.76) 14.95 (2.61) 16.20 (2.83)
WTAR 93.45 (12.59) 93.17 (12.87) 100.31 (8.87) 101.12 (8.58) 102.10 (8.77) 103.25 (7.95)
N.B. Values provided for point of study entry. Data are Mean (SD) or N (%).
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Change in cognitive performance of
patients compared to controls over
18 months
When comparing patients and controls over time, both groups
showed a significant effect of time on WAIS-IV FSIQ
(P = 0.026), PRI (P = 0.044), D-KEFS Tower Total
(P = 0.012), and Rule Violations Per Item Ratio (P = 0.022);
and on WMS-IV LM I (P = 0.021), LM II (P = 0.021), LM
Recognition (P = 0.021), and VPA I (P = 0.021). There were
no significant interactions (Table S2A–C).
Predictors of cognition in patients with
mitochondrial disease
Table 3 describes predictors of cognitive ability in patients
with mitochondrial disease.
Premorbid cognition
WTAR showed a positive relationship with number of
years in education, and a negative relationship with
NMDAS, and anticonvulsant medication, accounting for
55.7% of the variance in WTAR FSIQ.
General cognitive functioning
WTAR FSIQ was a significant, positive predictor of all
WAIS-IV scores. Disease-specific factors also showed a
significant negative relationship with performance on all
but WMI. Additionally, BAI was a significant negative
predictor of WAIS-IV FSIQ, the BDI was a significant
negative predictor of PRI, and age was a significant posi-
tive predictor of WMI. Variance accounted for by the
models ranged from 55.2% to 80.2%.
Executive function
WTAR FSIQ had a significant positive relationship with all
D-KEFS subtests except VF Letter and Tower Move Accu-
racy Ratio, while disease-specific factors showed a signifi-
cant negative relationship with all D-KEFS subtests.
Anticonvulsant medication showed a significant negative
relationship with VF Letter, female gender showed a posi-
tive relationship with both VF Switching Correct and
Switching Accuracy, and BAI was a significant negative pre-
dictor of Tower Time Per Move Ratio. Additionally, there
was a significant interaction between WTAR and NMDAS
on VF Category; NMDAS had a greater effect on perfor-
mance as WTAR increased (Fig. S2). A significant interac-
tion between WTAR FSIQ and % mtDNA mutation level
in urine on Tower Total showed that WTAR had a signifi-
cant positive affect on Tower Total at lower % mtDNA
mutation levels, but did not affect performance for those
with higher % mtDNA mutation levels (Fig. S3). The sig-
nificant interaction between WTAR FSIQ and mtDNA
genotype on Tower Rule Violations Per Item Ratio (using
transformed (squared) scores to correct for nonnormality
of unstandardized residuals) showed that patients with the
m.8344A>G point mutation who had lower premorbid
cognitive ability (as assessed by WTAR) made more rule
violations than patients with the m.3243A>G mutation, or
patients with m.8344A>G and higher premorbid cognitive
ability (Fig. S4). Variance accounted for by the models ran-
ged from 27.3% to 75.7%.
Memory
WTAR was the most influential predictor of memory in
patients. Anticonvulsant medication showed a significant
negative relationship with LM I performance and BDI was
a significant negative predictor of VPA I and VPA II. Dis-
ease-specific factors significantly predicted performance on
only VPA II and VPA Free Recall (Table 3). Variance
accounted for by the models ranged from 33.9% to 76.0%.
Change in cognition from premorbid to baseline
levels
Change in cognition from premorbid estimates to base-
line levels had a significant negative relationship with %
mtDNA mutation level in urine and NMDAS and
accounted for 42.4% of the variance (Fig. S5).
Discussion
We sought to systematically investigate cognition in a
well-defined cohort of patients with m.3243A>G and
m.8344A>G-related mitochondrial disease. Following
identification of deficits compared to normative data, we
compared patients to control participants matched by
premorbid cognitive ability, in an attempt to define the
effect of baseline cognition. This study showed mild-to-
moderate premorbid cognitive difficulties, that is, the
group distribution was lower overall than the national
expectations for intellectual attainment. Patients also
showed substantial impairment in current functioning in
the domains of verbal comprehension, perceptual reason-
ing, working memory, and processing speed (after correc-
tion for motor speed difficulties). Compared to matched
controls, patients performed worse on all domains, except
memory and executive function. With regards to mem-
ory, patients did demonstrate substantial memory retrie-
val difficulties; however, this did not vary significantly
from our control population, who had the same level of
baseline IQ.
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Table 3. Linear models showing predictors of cognitive ability in patients with mitochondrial disease.
Test B (CI) SE B b P R2
WTAR FSIQ 0.557
(Constant) 75.08 (60.20, 89.97) 7.39 <0.001
No. of years in education 1.99 (1.00, 2.98) 0.49 0.41 <0.001
NMDAS 0.24 (0.45, 0.03) 0.10 0.25 0.026
Anticonvulsant medication 11.97 (17.80, 6.13) 2.90 0.45 <0.001
WAIS-IV
FSIQ 0.802
(Constant) 32.44 (10.09, 54.78) 11.09 0.005
WTAR FSIQ 0.76 (0.56, 0.97) 0.10 0.58 <0.001
% mtDNA mutation level in urine 0.16 (0.25, 0.07) 0.04 0.25 0.001
BAI 0.56 (0.80, 0.32) 0.12 0.36 <0.001
VCI 0.777
(Constant) 11.92 (6.82, 30.66) 9.31 0.207
WTAR FSIQ 0.86 (0.68, 1.04)) 0.09 0.78 <0.001
NMDAS 0.18 (0.35, 0.01) 0.08 0.17 0.039
PRI 0.552
(Constant) 41.43 (9.00, 73.87) 16.10 0.013
WTAR FSIQ 0.70 (0.41, 1.00) 0.15 0.51 <0.001
% mtDNA mutation level in urine 0.16 (0.29, 0.02) 0.07 0.24 0.026
BDI 0.34 (0.61, 0.07) 014 0.27 0.015
WMI 0.593
(Constant) 4.78 (27.39, 17.84) 11.23 0.673
WTAR FSIQ 0.82 (0.59, 1.05) 0.11 0.69 <0.001
Age 0.32 (0.08, 0.55) 0.12 0.26 0.010
PSI 0.665
(Constant) 58.56 (24.25, 92.88) 17.03 0.001
WTAR FSIQ 0.55 (0.23, 0.86) 0.16 0.35 0.001
% mtDNA mutation level in urine 0.24 (0.37, 0.11) 0.07 0.34 0.001
NMDAS 0.58 (0.87, 0.29) 0.15 0.40 <0.001
D-KEFS
VF Letter 0.457
(Constant) 11.11 (9.68, 12.53) 0.71 <0.001
NMDAS 0.11 (0.17, 0.05) 0.03 0.41 0.001
Anticonvulsant medication 2.92 (4.71, 1.14) 0.89 0.39 0.002
VF category 0.757
(Constant) 10.14 (21.18, 0.91) 5.47 0.071
WTAR FSIQ 0.23 (0.12, 0.35) 0.06 0.72 <0.001
% mtDNA mutation level in urine 0.04 (0.07, 0.02) 0.01 0.27 0.002
NMDAS 0.31 (0.10, 0.72) 0.20 1.05 0.134
WTAR FSIQ * NMDAS 0.01 (0.01, 0.00) 0.00 1.39 0.031
VF switching correct 0.454
(Constant) 0.97 (10.30, 8.35) 4.63 0.834
WTAR FSIQ 0.10 (0.02, 0.19) 0.04 0.30 0.023
NMDAS 0.11 (0.19, 0.02) 0.04 0.33 0.014
Gender 3.00 (1.09, 4.92) 0.95 0.35 0.003
VF switching accuracy 0.446
(Constant) 2.38 (5.27, 10.03) 3.80 0.534
WTAR FSIQ 0.08 (0.01, 0.15) 0.04 0.28 0.035
NMDAS 0.10 (0.17, 0.03) 0.03 0.37 0.006
Gender 2.16 (0.58, 3.73) 0.78 0.31 0.008
Tower total 0.444
(Constant) 27.26 (11.27, 43.26) 7.94 0.001
WTAR FSIQ 0.17 (0.33, 0.00) 0.08 0.72 0.046
% mtDNA mutation level in urine 0.40 (0.63, 0.18) 0.11 3.62 0.001
WTAR FSIQ * % mtDNA mutation level in urine 0.00 (0.00, 0.01) 0.00 3.23 0.002
(Continued)
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High rates of general and specific cognitive impair-
ment, compared to the norm and to matched controls,
were identified, broadly corroborating previous litera-
ture.2–4,6–9,23 We identified relative strengths in perceptual
reasoning compared to processing speed. Although a
seven point difference between two cognitive domains
(PRI and PSI), is not rare within the general popula-
tion,13 37% of the sample showed a clinically significant
difference (>1SD difference). Executive function perfor-
mance was more variable and impairments may
potentially be caused by other difficulties (e.g. word gen-
eration; slow but accurate decision-making). These find-
ings are in contrast with other studies, that report clear
evidence of executive dysfunction.2,3,6,11 Indeed, our
results would suggest that these deficits, in part, may
result from slower decision-making.
This study also found that, although immediate and
delayed free recall were significantly worse than the norm,
heightened recognition performance demonstrated diffi-
culties with memory retrieval, rather than encoding or
Table 3. Continued.
Test B (CI) SE B b P R2
Tower time per move ratio 0.423
(Constant) 1.52 (7.03, 10.08) 4.25 0.721
WTAR FSIQ 0.10 (0.03, 0.18) 0.04 0.34 0.010
% mtDNA mutation level in urine 0.04 (0.08, 0.01) 0.02 0.30 0.013
BAI 0.09 (0.18, 0.00) 0.04 0.26 0.042
Tower move accuracy ratio 0.273
(Constant) 8.03 (6.84, 9.22) 0.59 <0.001
NMDAS 0.10 (0.05, 0.15) 0.02 0.52 <0.001
Tower rule violations per item ratio (squared) 0.483
(Constant) 224.16 (51.84, 396.47) 85.56 0.012
WTAR FSIQ 1.17 (3.02, 0.68) 0.92 0.43 0.209
mtDNA genotype 195.09 (320.62, 69.57) 62.32 2.55 0.003
WTAR FSIQ * mtDNA genotype 1.89 (0.50, 3.27) 0.69 2.16 0.009
WMS-IV
LM I 0.445
(Constant) 4.17 (11.68, 3.35) 3.73 0.270
WTAR FSIQ 0.13 (0.06, 0.21) 0.04 0.46 0.001
Anticonvulsant medication 2.25 (4.27, 0.23) 1.00 0.30 0.030
LM II 0.339
(Constant) 6.27 (12.00, 0.53) 2.85 0.033
WTAR FSIQ 0.15 (0.09, 0.21) 0.03 0.58 <0.001
VPA I 0.523
(Constant) 4.27 (10.52, 1.97) 3.10 0.175
WTAR FSIQ 0.16 (0.10, 0.22) 0.03 0.57 <0.001
BDI 0.08 (0.14, 0.02) 0.03 0.30 0.007
VPA II 0.475
(Constant) 1.98 (6.00, 9.97) 3.96 0.619
WTAR FSIQ 0.13 (0.05, 0.20) 0.04 0.40 0.001
% mtDNA mutation level in urine 0.04 (0.07, 0.00) 0.02 0.24 0.037
BDI 0.09 (0.16, 0.03) 0.09 0.03 0.008
VPA free recall 0.760
(Constant) 5.24 (11.02, 0.54) 2.87 0.074
WTAR FSIQ 0.19 (0.14, 0.24) 0.03 0.62 <0.001
% mtDNA mutation level in urine 0.03 (0.05, 0.01) 0.01 0.21 0.009
NMDAS 0.08 (0.13, 0.03) 0.03 0.28 0.003
Change in cognition from premorbid to baseline levels
WTAR-WAIS-IV change 0.424
(Constant) 7.43 (1.10, 13.76) 3.14 0.022
% mtDNA mutation level in urine 0.16 (0.25, 0.07) 0.05 0.001
NMDAS 0.32 (0.51, 0.13_ 0.09 0.001
Abbreviations: WTAR FSIQ: Wechsler test of adult reading; WAIS-IV: Wechsler adult intelligence scale-IV; FSIQ: FSIQ; VCI: verbal comprehension
index; PRI: perceptual reasoning index; WMI: working memory index; PSI: processing speed index; D-KEFS VF: Delis-Kaplan executive function
score verbal fluency; LM: logical memory; VPA: verbal paired associates; BDI: Beck’s depression inventory; BAI: Beck’s anxiety inventory; NMDAS:
Newcastle mitochondrial disease adult scale.
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storage. Furthermore, patients did not differ from con-
trols on any of the WMS-IV memory tests, indicating that
while memory problems do exist, those difficulties are no
worse than would be expected based on premorbid cogni-
tive ability. Previous studies interrogating memory have
demonstrated inconsistencies2,3,6,9–11 while this study
clearly identifies memory retrieval as the impaired step in
this process.
Patients with m.3243A>G and m.8344A>G-related
mitochondrial disease showed cognitive decline from pre-
morbid estimates to current levels, and while mean
decline was eight IQ points, 28% showed declines of
>1SD. Despite this suggestion of longer term decline,
patients showed the same pattern of cognitive improve-
ments as controls over the length of this study, in line
with practice effects caused by familiarity, and indicative
of normal learning ability. However, given that premorbid
cognitive ability of matched pairs was within the normal
range, conclusions can only be drawn about patients
within this range. It cannot be inferred whether the same
pattern of results would be found for those with lower
premorbid cognition (and worse disease profile), who
might show differential practice effects or sharper cogni-
tive declines over time. While this group analysis does
not allow discussion of individual variability, using our
robust cognitive battery, this may help delineate decline
in specific domains in more severely affected patient pop-
ulations. In this sample, the contrasting results indicating
both decline and stability may suggest slow changes over
a longer period than is measured here7 and/or sudden
declines linked to discrete changes in other disease-speci-
fic factors. In keeping with this, disease severity, measured
by the NMDAS, remained stable over the 18-month fol-
low-up period (Table S2D); thus, disease-specific factors
that might impact cognitive change were unlikely to trig-
ger cognitive decline. Importantly, with 15% patient attri-
tion at 18 months, caused by general health deterioration,
a different pattern may have emerged had this subsample
remained. It is important to recognize the possibility of
individual variability in day-to-day functioning in patients
with mitochondrial disease,24–27 which could impact on
cognitive performance each time participants are assessed.
However, long-term, regular observation would be neces-
sary to identify disease-related within person variability in
cognition, and still, practice effects would make it chal-
lenging to capture this variability.
Premorbid cognitive ability was a significant predictor
of many areas of cognition, as seen in normal popula-
tions.28,29 More interestingly, we found a significant nega-
tive relationship between disease severity and some
measures of current cognition, as opposed to genotypic
differences identified previously,23 and change in cogni-
tion (WTAR-WAIS-IV) was predicted solely by disease
severity, that was not unduly impacted by central nervous
system involvement, as assessed by NMDAS. Indeed,
mtDNA genotype only predicted that patients harboring
the m.8344A>G mutation who had lower premorbid cog-
nition made more rule violations on the Tower test.
However, caution is required when interpreting differ-
ences caused by mtDNA genotype, given the small num-
bers of m.8344A>G patients. Additionally, anticonvulsant
medication and mood negatively predicted different cog-
nitive abilities. While our sample size is small and allowed
little power for these analyses (requiring validation with
larger samples), it is the largest systematic investigation of
distinct cognitive domains in patients to date.2–11,23
An inherent limitation is that while WTAR is a reliable
tool for estimating peak cognition before onset of decline
caused by illness/injury30,31; reading tests are not com-
pletely impervious to cerebral insult,32–34 and it is
unknown how cerebral damage affects reading ability in
patients. However, mixed effect modeling using WTAR
data from the MRC Mitochondrial Disease Cohort UK
(576 observations from 157 patients harboring either the
m.3243A>G or m.8344A>G mutation, with two or more
WTAR scores) showed that, after accounting for between-
patient variability, there was no significant change in
WTAR score over time (P > 0.05). This confirms its sta-
bility over multiple assessments and supports use of the
WTAR as an analogue for premorbid cognition in this
patient cohort.
Conclusions
These findings have important implications for clinical
practice and for the advice provided to ameliorate every-
day difficulties when cognitive problems present in this
subset of patients. Early educational support, to ensure
that children with mitochondrial disease achieve their full
potential, may provide protective effects against later cog-
nitive difficulties. Indications of slow cognitive decline
suggest that patients should be monitored over time to
identify difficulties early, and if cognitive difficulties do
develop, appropriate compensatory strategies should be
identified through in-depth cognitive assessment. When
considering clinical trials, this in-depth cognitive profile
would also be invaluable for assessing the impact of any
potential therapies. In clinical practice, healthcare profes-
sionals should be alert to disease-specific factors, which
may increase the likelihood of cognitive difficulties, and
monitor those individuals more closely. Healthcare pro-
fessionals should also be mindful of how cognitive diffi-
culties may influence understanding of information and
subsequent ability to provide informed consent, and con-
sider how this risk might be mitigated. Practical steps that
can be taken in everyday life, as well as in clinical settings,
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could include using strategies such as slower presentation
of information; multiple modes of presentation to rein-
force information and exploit relative cognitive strengths;
active discussion to aid understanding and decision-mak-
ing; and memory aids, including repetition and cues.
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Figure S1. WAIS-IV PSI performance, controlling for
motor speed.
Figure S2. Relationship between WTAR FSIQ and D-
KEFS VF Category, grouped by NMDAS level. NMDAS
was split into two groups using the mean of 20.
Figure S3. Relationship between WTAR FSIQ and D-
KEFS Tower Total, grouped by % mtDNA mutation level
in urine. % mtDNA mutation level in urine was split into
two groups using the mean of 60.
Figure S4. Relationship between WTAR FSIQ and D-
KEFS Tower Rule Violations Per Item Ratio (squared),
grouped by mtDNA genotype.
Figure S5. Relationship between % mtDNA mutation
level in urine and NMDAS on change in cognition, from
premorbid estimates to baseline levels. NMDAS was split
into two groups using the mean of 20.
Table S1. Patient cognitive performance compared to
normative data.
Table S2. (A) Patient WAIS-IV performance over time
and in comparison to matched controls. (B) Patient D-
KEFS performance over time and in comparison to
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time and in comparison to matched controls. (D) Patient
NMDAS scores over time.
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analyses.
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